STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Overview

Inspira Technologies Oxy BHN Ltd (IINN) is a specialty medical device company committed to transforming the landscape of respiratory care. With a focus on life support and respiratory treatment, the company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART) that provides a non-invasive alternative to traditional mechanical ventilation. The technology is designed to elevate oxygen saturation and reduce carbon dioxide levels in patients, addressing a critical need in the management of acute respiratory failure.

Core Technology and Innovation

The hallmark of Inspira Technologies is its pioneering approach to respiratory support. Its INSPIRA ART system employs advanced principles of extracorporeal oxygenation, substituting the direct mechanical intervention of traditional ventilators with a sophisticated intravascular apparatus. This device promises to stabilize oxygen levels rapidly without the complications that are often associated with mechanical ventilation, thereby offering patients the possibility of remaining awake during treatment.

Complementing the INSPIRA ART is the company’s innovative HYLA blood sensor technology. This AI-powered continuous monitoring system provides real-time data on a patient’s blood oxygenation and carbon dioxide levels, allowing healthcare professionals immediate access to critical parameters. The integration of HYLA enhances the utility of the INSPIRA ART, offering continuous feedback and contributing to a more informed clinical decision-making process.

Market Significance and Competitive Position

Inspira Technologies operates in a competitive yet rapidly evolving segment of the medical devices market. The problems associated with invasive mechanical ventilation, such as high treatment costs, complications, and a heavy burden on ICU resources, position the company’s offerings as potentially disruptive in a market that handles millions of cases of acute respiratory failure annually. By addressing both the mechanical and monitoring aspects of respiratory support through its dual technologies, the company is carving out a unique position that resonates with healthcare providers who seek safer, more efficient, and patient-centric solutions.

Regulatory Achievements and Clinical Insights

The company has achieved significant regulatory milestones, obtaining clearance for its INSPIRA ART systems in key procedures such as Cardiopulmonary Bypass. These clearances underscore the robustness and safety of its design. Additionally, the clinical evaluations of its HYLA blood sensor technology at internationally recognized medical institutions demonstrate the company’s commitment to aligning innovation with established clinical protocols and standards.

Product Portfolio and Operational Excellence

Beyond its flagship INSPIRA ART system and the supporting HYLA sensor, Inspira Technologies is actively developing a robust pipeline of products aimed at addressing various facets of respiratory support and blood monitoring. The company’s research, development, manufacturing, and marketing operations are tailored to meet the rigorous demands of modern critical care, emphasizing ease of use, rapid response, and integration with existing hospital systems.

Strategic Collaborations and Global Reach

Recognizing the global need for improved respiratory care, Inspira Technologies has engaged in strategic collaborations with leading hospitals and distributors across multiple regions including North America, Europe, and Asia Pacific. These partnerships not only validate the technological merits of the company’s products but also help penetrate diverse healthcare markets that continue to rely heavily on traditional ventilation methods.

Commitment to Quality and Clinical Impact

The company’s approach blends robust technological innovation with a keen understanding of clinical challenges. By focusing on continuous innovation through rigorous trial evaluations, adherence to regulatory standards, and integration of AI-powered analytics, Inspira Technologies is dedicated to enhancing patient outcomes in critical care settings while alleviating operational burdens on healthcare providers.

Conclusion

Inspira Technologies Oxy BHN Ltd represents a thoughtful blend of technical innovation and clinical pragmatism. It stands out for its effort to revolutionize respiratory support through cutting-edge non-invasive technologies that offer an alternative to conventional mechanical ventilation. With a comprehensive business model centered on enhancing both patient care and operational efficiency in critical care environments, the company is well-positioned in its sector as healthcare institutions increasingly seek solutions that combine safety, rapid responsiveness, and sustained reliability.

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) announced a 5-year exclusive distribution agreement with Innovimed for the HYLA™ Blood Sensor, designed for continuous real-time blood parameter monitoring. The agreement requires Innovimed to purchase at least 1,364 sensors and 128,511 disposable units for hospitals in Poland, Czech Republic, and Slovakia. The collaboration aims to enhance market penetration in Europe while preparing for a clinical study of the HYLA™ Blood Sensor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) announced that the Israeli Patent Office has granted a patent for a key component of its INSPIRA ART system. This component, designed to secure a neck cannula, aims to enhance patient mobility and safety during treatment, potentially reducing reliance on invasive mechanical ventilation. The company plans to seek patent protections globally and is also considering early market entry for the component in the ECMO device market, which is valued at $531 million annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) announced its participation in the iECOs Conference happening on November 10, 2022, in Tel Aviv, Israel. The company's CTO, Daniella Yeheskely-Hayon, Ph.D., will deliver a guest lecture during the Physiology and Technology session, showcasing Inspira's innovative respiratory support technology. This technology aims to enhance patient oxygen saturation levels while minimizing the need for invasive procedures. Additionally, the scientific team will be available at their booth to provide insights and answer questions about their ongoing product developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
conferences
Rhea-AI Summary

Inspira Technologies (NASDAQ:IINN, IINNW) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on October 22, 2022, at 7 p.m. ET. During the interview, President Joe Hayon will discuss the Company's InspiraART System and HYLA blood sensor, highlighting significant market opportunities and their product pipeline. The InspiraART technology aims to improve patient oxygen saturation while reducing reliance on invasive mechanical ventilation. The technology is yet to be tested in humans and is pending regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
Rhea-AI Summary

On September 7, 2022, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced the completion of an animal study for its HYLA™ blood sensor at Lahav C.R.O. The sensor, which is non-invasive, offers real-time measurements of blood parameters, potentially improving patient monitoring and reducing risks compared to standard blood gas analyzers. The successful animal study follows earlier laboratory data and marks a significant step toward initiating human studies. This advancement is integral to Inspira's innovative respiratory support technology aimed at enhancing patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that President Joe Hayon will present at the H.C. Wainwright 24th Annual Global Investor Conference on September 12, 2022, at 7:00 a.m. ET. One-on-one meetings with Hayon will take place on September 13-14, 2022. Inspira Technologies is known for its innovative Augmented Respiration Technology, aimed at improving patient oxygen saturation without invasive procedures. The technology is not yet approved for human use. For further details, visit their Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q2 2022 financial results, highlighting a net loss of $3.5 million, down from $8.2 million a year earlier. Cash reserves stood at $19.2 million as of June 30, 2022. The company's R&D expenses rose to $2.7 million, driven by increased projects and share-based compensation. Inspira introduced the HYLA™ non-invasive blood sensor and revealed the ALICE™ Device for cardiopulmonary bypass, targeting respective markets of $2.5 billion and significant deployment agreements in Israel and the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
-
Rhea-AI Summary

Inspira Technologies has introduced the Liby™ System, a next-generation extracorporeal membrane oxygenation (ECMO) device aimed at the $531 million global ECMO market. The company plans to submit for FDA approval in the first half of 2023, anticipating a Class II 510(k) designation that may not require human trials. The Liby™ system features innovative capabilities such as continuous patient monitoring integration with HYLA™ technology, reducing medical care costs through a consumable sales model.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.35%
Tags
none
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has unveiled the Liby™ System, a new extracorporeal membrane oxygenation (ECMO) device designed to treat severe heart and lung failure. Targeting a $531 million global ECMO market, the system is set for FDA submission in H1 2023 and may qualify as a Class II 510(k) device, potentially bypassing human trials. The Liby™ system aims to enhance patient mobility and usability in ICUs, generating recurring revenue through disposable kits, similar to its ART™ system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
Rhea-AI Summary

Inspira Technologies has signed a strategic agreement with Glo-Med Networks for the potential distribution of the HYLA™ Blood Sensors across six US states over three years, pending regulatory approvals. This contract includes a minimum purchase commitment of 3,889 sensors and 264,873 disposable units, potentially worth $59 million. This agreement follows a previous contract for the ART™ system and positions Inspira for significant growth in the medical device market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none

FAQ

What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?

The current stock price of Inspira Technologies Oxy Bhn (IINN) is $0.6691 as of April 2, 2025.

What is the market cap of Inspira Technologies Oxy Bhn (IINN)?

The market cap of Inspira Technologies Oxy Bhn (IINN) is approximately 17.0M.

What is the core business of Inspira Technologies Oxy BHN Ltd?

Inspira Technologies focuses on developing innovative respiratory support and life support technologies that serve as alternatives to invasive mechanical ventilation.

How does the INSPIRA ART system differ from traditional mechanical ventilators?

The INSPIRA ART system is designed to enhance oxygen levels and remove carbon dioxide using an intravascular approach, potentially reducing complications and allowing patients to remain awake during treatment.

What role does the HYLA blood sensor technology play in Inspira's product portfolio?

The HYLA blood sensor provides real-time, continuous monitoring of blood parameters, enabling immediate clinical feedback and supporting informed decisions during respiratory treatment.

Which market segments does Inspira Technologies serve?

The company targets the respiratory care and life support markets globally, with applications in intensive care units, operating rooms, and other critical care settings.

What regulatory achievements has Inspira Technologies accomplished?

Inspira Technologies has obtained key regulatory clearances, such as FDA 510(k) clearance for its INSPIRA ART systems in procedures like Cardiopulmonary Bypass, underscoring its commitment to safety and clinical efficacy.

How do Inspira Technologies' solutions benefit healthcare providers?

By offering non-invasive respiratory support and continuous blood monitoring, the company’s technologies can improve patient care, reduce the complications associated with traditional ventilation, and provide rapid clinical information.

What distinguishes Inspira Technologies within the competitive medical device market?

The company combines breakthrough respiratory support technology with advanced, AI-powered blood monitoring, positioning it uniquely against traditional ventilation methods and addressing key clinical challenges.
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

17.00M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana